This video reviews immunotherapy trials in small-cell lung cancer, including studies on pembrolizumab, nivolumab monotherapy, and nivolumab in combination with ipilimumab.
Immunotherapy has shown efficacy in lung cancer, with several drugs already approved for patients with non–small-cell lung cancer (anti–PD-1 agent nivolumab, anti–PD-L1 agents pembrolizumab and atezolizumab).
In this video, Gregory P. Kalemkerian, MD, of the University of Michigan Health System, discusses immunotherapies in the small-cell lung cancer (SCLC) setting.
Kalemkerian reviews the results of several trials in SCLC, including nivolumab monotherapy or in combination with the CTLA-4 blocker ipilimumab, and pembrolizumab.
Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer
September 18th 2018ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.